Free Newsletter
Targets found for antibiotic development
Researchers at the University of Alabama at Birmingham have new information on the structure of a key enzyme in bacteria that could lead to improved antibiotics and less antibiotic resistance. In findings published online in two complementary papers in Nature, the research team describes the differences in an enzyme called RNA polymerase in bacterial cells as opposed to human cells. These differences provide potential new targets for drug design.
"Knowing how RNA polymerase differs in human and bacterial cells means antibiotics can be designed with a greater probability that they will interact with and kill bacteria, while leaving healthy human cells alone," says Dmitry Vassylyev, Ph.D., professor of biochemistry and molecular genetics and lead author of both papers.
- check out the release on antibiotics
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: